It is not yet approved for general prescription
The triple mechanism hits weight loss from more angles simultaneously
Requires split draw
GLP-1 Key Research Facts Full name: Glucagon-Like Peptide-1 incretin hormone of the proglucagon family Primary bioactive form: GLP-1(736)amide 30 amino acids, C-terminally amidated Gene source: Proglucagon gene processed by PCSK1 in intestinal L-cells and brainstem NTS neurons In vivo half-life: Approximately 12 minutes rapidly inactivated by DPP-4 (cleaves His7-Ala8 dipeptide) Primary receptor: GLP-1R (GLP-1 receptor) class B G protein-coupled receptor (GPCR) Signalling: GLP-1R activation cAMP elevation PKA/CREB activation glucose-dependent insulin secretion Additional signalling: PI3K/Akt pathway -cell survival, proliferation, and glucose sensitivity Secretion pattern: Biphasic post-meal release from intestinal L-cells early neural/endocrine peak + late direct nutrient-contact peak Fasting plasma level: ~510 pmol/L

Key weight loss results at 48 weeks by group: Response rates at 48 weeks (12 mg dose): 100% achieved greater than or equal to 5% weight loss 93% achieved greater than or equal to 10% weight loss 83% achieved greater than or equal to 15% weight loss The cardiometabolic improvements were also significant, with reductions in blood pressure, triglycerides, LDL cholesterol, HbA1c, fasting glucose, and fasting insulin across all dose groups
When you track those conditions, you can respond with more understanding and less shame